HK Stock Connect Insight | SHOUGANG LANZA (02553.HK) First-Half Revenue Up 9.9% YoY, Included in Stock Connect from September 7

NewTimeSpace News: On October 27, 2026, SHOUGANG LANZA closed at HKD 11.49, down 2.63% for the day, with turnover of HKD 3.1944 million.

According to publicly available information, SHOUGANG LANZA listed on the Main Board of HKEX on June 3, 2026 at an offer price of HKD 14.60, with a global offering of 40 million H shares and net proceeds of approximately HKD 486 million. The Hong Kong public offering was oversubscribed 1,421.54 times.

Since its listing on June 3, 2026, the share price has ranged from a high of HKD 54.40 to a low of HKD 11.11. As of October 27, 2026, the stock closed at HKD 11.49, about 21.3% below the offer price of HKD 14.60. Since its inclusion in Stock Connect, the share price has fallen from HKD 20.08 at the close on September 7, 2026 to HKD 11.49, a cumulative decline of about 42.8%.

Hang Seng Indexes Company announced on August 21, 2026 the results of its quarterly review of the Hang Seng Index series for the period ended June 30, 2026, under which SHOUGANG LANZA was included in the Hang Seng Composite Index, with the constituent change effective on September 7, 2026. The Shanghai and Shenzhen stock exchanges subsequently adjusted their respective lists of eligible securities under Stock Connect, and the company's H shares were included in the list of eligible securities for Stock Connect with effect from September 7, 2026.

Founded in 2011 and headquartered in Beijing, SHOUGANG LANZA is a biomanufacturing enterprise deeply engaged in the carbon capture, utilisation and storage (CCUS) industry and listed on HKEX in June 2026. With gas fermentation technology at its core, the company biologically converts carbon-containing industrial off-gas from steel and ferroalloy production into low-carbon products such as ethanol and microbial protein.

On the financial front, the company's revenue for the first half of 2026 was RMB 293 million, up 9.9% year on year, of which revenue from ethanol was RMB 241 million, up 10.5% year on year, and revenue from microbial protein was RMB 49.4 million, up 8.1% year on year. Loss for the period was RMB 118 million, narrowed by 30.1% year on year. The Phase II production facility of Hebei Shoulang achieved successful trial production in June 2026, marking the full-process commissioning of the world's first 10,000-tonne-scale project for the biosynthesis of anhydrous ethanol from CO2-containing industrial off-gas.

A research report by CITIC Securities noted that the company is a specialised and sophisticated leader in AI-enabled synthetic biology CCUS, and that its near-term results are under pressure from fluctuations in gas supply and ethanol prices. As its products mature and come to market and capacity at its four major bases continues to recover, the company is expected to ease gas supply constraints through park gas supply projects and to open up incremental growth through a technology licensing model, with multiple new business pipelines such as sustainable aviation fuel, green polyethylene and bioactive peptides advancing in parallel, leaving ample room for medium- to long-term development.